13940-96-0

Basic information

• Product Name: 3,4'-OXYDIANILINE
• Synonyms: 4-Phenoxy-1,2-phenylenediamine;3,4-Diaminodiphenyl ether;4-Phenoxybenzene-1,2-diaMine
• CAS NO: 13940-96-0
• Molecular Formula: C₁₂H₁₂N₂O
• Molecular Weight: 200.24
• Mol File: 13940-96-0.mol
• Article Data: 11

Chemical Properties

• Melting Point: 69 °C
• Boiling Point: 365.2±27.0 °C(Predicted)
• Appearance: /
• Density: 1.216±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 4.32±0.10(Predicted)
• CAS DataBase Reference: 3,4'-OXYDIANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4'-OXYDIANILINE(13940-96-0)
• EPA Substance Registry System: 3,4'-OXYDIANILINE(13940-96-0)

Safety Data

• Hazardous Substances Data: 13940-96-0(Hazardous Substances Data)

Usage

General Description

3,4'-Oxydianiline, also known as 4,4'-Methylenedianiline or 4,4'-Oxydianiline, is an organic compound that is commonly used as a curing agent in the production of polyurethane polymers and epoxy resins. It is a colorless to pale yellow solid with a slightly sweet odor, and it is highly reactive and can cause severe burns upon contact with the skin and eyes. Exposure to 3,4'-Oxydianiline can also cause respiratory irritation, nausea, and dizziness. Due to its potential health hazards, proper handling and protective equipment are necessary when working with this chemical. Additionally, its use is regulated by government agencies to ensure safe handling and disposal practices.

Upstream product

• 108-95-2 phenol 
• 116435-85-9 4-phenoxybenzene-1,2-diamine 
• 2369-11-1 5-fluoro-2-nitroaniline 
• 1635-61-6 5-chloro-2-nitroaniline 
• 1552-17-6 2-nitro-5-phenoxyaniline 
• 60853-99-8 N-(2-nitro-4-phenoxyphenyl)acetamide 
• 60854-00-4 2-nitro-4-phenoxyphenylamine 
• 58306-60-8 acetic acid-(2-amino-4-phenoxy-anilide) 

Downstream Products

• 1552-17-6 2-nitro-5-phenoxyaniline 
• 1262116-57-3 2-(4-bromophenyl)-6-(6-phenoxy-1H-benzo[d]imidazol-2-yl)-N-phenylimidazo[1,2-a]pyridin-3-amine 
• 1262116-51-7 6-(6-phenoxy-1H-benzo[d]imidazol-2-yl)-N-phenyl-2-p-tolylimidazo[1,2-a]pyridin-3-amine 
• 1246788-08-8 C₂₀H₁₆N₂O₂ 
• 43155-38-0 methyl (5-phenoxy-1H-benzo[d]imidazol-2-yl)carbamate 
• 1092779-22-0 C₂₁H₁₅ClN₂O₄ 

Relevant articles and documents

PqsR INVERSE AGONISTS

The present invention relates to a compound according to general formula (I), which acts as an inhibitor of PqsR (the currently only known receptor for the Pseudomonas Quinolone Signal (PQS)); to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament, e.g. the use in the treatment or prophylaxis of a bacterial infection, especially a Pseudomonas aeruginosa or Burkholderia infection.

5 - [...] -2 alkyl substituted [...] and imidazole compound and use thereof

The present invention discloses a 5-aryl phenol-2 alkyl substituted urea benzimidazole compound and applications thereof, wherein the compound has a structure represented by a formula (I). According to the present invention, the 5-aryl phenol-2 alkyl subs

New benzimidazole-2-urea derivates as tubulin inhibitors

Emerging drug resistance and other drawbacks limit tubulin inhibitors' therapeutic applications and developing novel tubulin inhibitors still attracts intensive efforts. We describe the discovery and structure-activity relationship study of a series of benzimidazole-2-urea derivatives as novel β tubulin inhibitors. The representative compound 6o potently suppressed the proliferation of a panel of human cancer cells (NCI-H460, Colo205, K562, A431, HepG2, Hela, MDA-MB-435S) with IC50 values of 0.040, 0.050, 0.006, 0.026, 1.774, 0.452 and 0.052 μM, respectively. Compound 6o obviously inhibited NCI-H460 spindles formation and induced cell cycle arrest at G2/M phase at 0.10 μM. Computational study suggested that 6o interacts with β tubulin in a novel binding mode. Our results suggested that benzimidazole-2-urea derivatives might be promising tubulin inhibitors with novel binding mode for further development.